V. Chiosa, D. Ciolac, V. Chelban, Daniela Gasnas, A. Vataman, C. Munteanu, S. Groppa
{"title":"耐药癫痫:现代概念、综合机制和治疗进展","authors":"V. Chiosa, D. Ciolac, V. Chelban, Daniela Gasnas, A. Vataman, C. Munteanu, S. Groppa","doi":"10.52418/moldovan-med-j.64-4.21.14","DOIUrl":null,"url":null,"abstract":"Background: Drug-resistant epilepsy is the cause of severe disability. Multiple questions remain unanswered both in terms of pathogenesis and therapeutic management. For this narrative review, PubMed database and Infomedica library were searched by using “drug-resistance in epilepsy” and “treatment of drug-resistant epilepsy” as key words. The following filters were applied: “Clinical Trial”, “Meta-analysis”, “Multicenter Study”, and “Randomized Controlled Trial”, covering the period of 01.01.2005–06.01.2021.Several hypotheses have been proposed, i.e., pharmacokinetic, intrinsic severity, gene, target, transporter, and neural network hypotheses. Many controlled trials showed different results in terms of seizure control after combined methods of therapies. Immunotherapy, palliative epilepsy surgery alone or associated with neurostimulation procedures including vagus nerve, trigeminal nerve, or deep brain stimulation may be efficient, however, seizure freedom is not always achieved. Genetic epilepsies might benefit from gene and exosome therapy; however, further studies are needed to verify their safety. Conclusions: Neuroscience of drug-resistant epilepsy faces many challenges. Inflammatory mediators, biomarkers, and genes might allow the identification of new treatment targets, contribute to an earlier diagnosis, and assess the clinical outcomes.","PeriodicalId":32733,"journal":{"name":"The Moldovan Medical Journal","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Drug-resistant epilepsy: modern concepts, integrative mechanisms, and therapeutic advances\",\"authors\":\"V. Chiosa, D. Ciolac, V. Chelban, Daniela Gasnas, A. Vataman, C. Munteanu, S. Groppa\",\"doi\":\"10.52418/moldovan-med-j.64-4.21.14\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Drug-resistant epilepsy is the cause of severe disability. Multiple questions remain unanswered both in terms of pathogenesis and therapeutic management. For this narrative review, PubMed database and Infomedica library were searched by using “drug-resistance in epilepsy” and “treatment of drug-resistant epilepsy” as key words. The following filters were applied: “Clinical Trial”, “Meta-analysis”, “Multicenter Study”, and “Randomized Controlled Trial”, covering the period of 01.01.2005–06.01.2021.Several hypotheses have been proposed, i.e., pharmacokinetic, intrinsic severity, gene, target, transporter, and neural network hypotheses. Many controlled trials showed different results in terms of seizure control after combined methods of therapies. Immunotherapy, palliative epilepsy surgery alone or associated with neurostimulation procedures including vagus nerve, trigeminal nerve, or deep brain stimulation may be efficient, however, seizure freedom is not always achieved. Genetic epilepsies might benefit from gene and exosome therapy; however, further studies are needed to verify their safety. Conclusions: Neuroscience of drug-resistant epilepsy faces many challenges. Inflammatory mediators, biomarkers, and genes might allow the identification of new treatment targets, contribute to an earlier diagnosis, and assess the clinical outcomes.\",\"PeriodicalId\":32733,\"journal\":{\"name\":\"The Moldovan Medical Journal\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Moldovan Medical Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.52418/moldovan-med-j.64-4.21.14\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Moldovan Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52418/moldovan-med-j.64-4.21.14","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景:耐药癫痫是严重致残的原因。在发病机制和治疗管理方面,许多问题仍未得到解答。本文以“drug-resistance in epilepsy”和“treatment of drug-resistant epilepsy”为关键词,检索PubMed数据库和infomemedica library。采用以下筛选:“临床试验”、“meta分析”、“多中心研究”、“随机对照试验”,时间为2005年1月1日至2021年6月1日。提出了几种假说,即药代动力学假说、内在严重性假说、基因假说、靶点假说、转运蛋白假说和神经网络假说。许多对照试验显示,在联合治疗方法后,癫痫发作的控制结果不同。单独的免疫治疗、姑息性癫痫手术或与神经刺激程序(包括迷走神经、三叉神经或深部脑刺激)相关的治疗可能是有效的,然而,癫痫发作并不总是能够得到缓解。遗传性癫痫可能受益于基因和外泌体治疗;然而,需要进一步的研究来验证它们的安全性。结论:耐药癫痫的神经科学研究面临诸多挑战。炎症介质、生物标志物和基因可能有助于识别新的治疗靶点,有助于早期诊断,并评估临床结果。
Drug-resistant epilepsy: modern concepts, integrative mechanisms, and therapeutic advances
Background: Drug-resistant epilepsy is the cause of severe disability. Multiple questions remain unanswered both in terms of pathogenesis and therapeutic management. For this narrative review, PubMed database and Infomedica library were searched by using “drug-resistance in epilepsy” and “treatment of drug-resistant epilepsy” as key words. The following filters were applied: “Clinical Trial”, “Meta-analysis”, “Multicenter Study”, and “Randomized Controlled Trial”, covering the period of 01.01.2005–06.01.2021.Several hypotheses have been proposed, i.e., pharmacokinetic, intrinsic severity, gene, target, transporter, and neural network hypotheses. Many controlled trials showed different results in terms of seizure control after combined methods of therapies. Immunotherapy, palliative epilepsy surgery alone or associated with neurostimulation procedures including vagus nerve, trigeminal nerve, or deep brain stimulation may be efficient, however, seizure freedom is not always achieved. Genetic epilepsies might benefit from gene and exosome therapy; however, further studies are needed to verify their safety. Conclusions: Neuroscience of drug-resistant epilepsy faces many challenges. Inflammatory mediators, biomarkers, and genes might allow the identification of new treatment targets, contribute to an earlier diagnosis, and assess the clinical outcomes.